发明名称 SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES
摘要 The invention relates to compounds that have an affinity to the μ-opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these compounds for the treatment of pain and other conditions.
申请公布号 US2014357634(A1) 申请公布日期 2014.12.04
申请号 US201414459540 申请日期 2014.08.14
申请人 GRÜNENTHAL GMBH 发明人 NOLTE BERT;SCHRÖDER WOLFGANG;LINZ KLAUS;ENGLBERGER WERNER;SCHICK HANS;GRAUBAUM HEINZ;ROLOFF BIRGIT;OZEGOWSKI SIGRID;BÁLINT JÓZSEF;SONNENSCHEIN HELMUT
分类号 C07D209/20;A61K45/06;C07D403/08;C07C211/54;A61K31/136;A61K31/5377;A61K31/165;C07C311/37;A61K31/18;C07D251/48;A61K31/53;A61K31/404;C07C237/24 主分类号 C07D209/20
代理机构 代理人
主权项 1. A compound of the formula (1): wherein Y1, Y1′, Y2, Y2′, Y3, Y3′, Y4 and Y4′ are respectively selected independently of one another from the group consisting of —H, —F, —Cl, —Br, —I, —CN, —NO2, —CHO, —R0, —C(═O)R0, —C(═O)H, —C(═O)—OH, —C(═O)OR0, —C(═O)NH2, —C(═O)NHR0, —C(═O)N(R0)2, —OH, —OR0, —OC(═O)H, —OC(═O)R0, —OC(═O)OR0, —OC(═O)NHR0, —OC(═O)N(R0)2, —SH, —SR0, —SO3H, —S(═O)1-2—R0, —S(═O)1-2NH2, —NH2, —NHR0, —N(R0)2, —N+(R0)3, —N+(R0)2O−, —NHC(═O)R0, —NHC(═O)OR0, —NHC(═O)NH2, —NHC(═O)NHR0 and —NHC(═O)N(R0)2; or Y1 and Y1′, or Y2 and Y2′, or Y3 and Y3′, or Y4 and Y4′ jointly stand for ═O; Q stands for —R0, —C(═O)—R0, —C(═O)OR0, —C(═O)NHR0, —C(═O)N(R0)2 or —C(═NH)—R0; R0 respectively independently stands for —C1-8-aliphatic, —C3-12-cycloaliphatic, -aryl, -heteroaryl, —C1-8-aliphatic-C3-12-cycloaliphatic, —C1-8-aliphatic-aryl, —C1-8-aliphatic-heteroaryl, —C3-8-cycloaliphatic-C1-8-aliphatic, —C3-8-cycloaliphatic-aryl or —C3-8-cycloaliphatic-heteroaryl; R1 and R2, independently of one another, stand for —H or —R0; or R1 and R2 jointly form a ring and stand for —CH2CH2OCH2CH2—, —CH2CH2NR4CH2CH2— or —(CH2)3-6—; on condition that R1 and R2 do not both simultaneously stand for —H; R3 stands for —R0; R4 respectively independently stands for —H, —R0 or —C(═O)R0; n stands for a whole number from 0 to 12; X stands for —O—, —S— or —NRA—; RA stands for —H, —R0, —S(═O)0-2R0, —C(═O)R0, —C(═O)OR0, —C(═O)NH2, —C(═O)NHR0 or —C(═O)N(R0)2; RB stands for —H, —R0, —C(═O)H, —C(═O)R0, —C(═O)OH, —C(═O)OR0, —C(═O)NH2, —C(═O)NHR0, —C(═O)N(R0)2, —S(═O)1-2—R0, —S(═O)1-2—OR0, —S(═O)1-2—NH2, —S(═O)1-2—NHR0 or —S(═O)1-2—N(R0)2; or RA and RB jointly form a ring and stand for —(CH2)2-5—, —CH2CH2OCH2CH2— or —CH2CH2NR4CH2CH2—; on condition that when X stands for —O— and at the same time n stands for 0, RB does not stand for —H; wherein “aliphatic” respectively is a branched or unbranched, saturated or a mono- or polyunsaturated, unsubstituted or mono- or polysubstituted, aliphatic hydrocarbon residue; “cycloaliphatic” respectively is a saturated or a mono- or polyunsaturated, unsubstituted or mono- or polysubstituted, alicyclic, mono- or multicyclic hydrocarbon residue; wherein with respect to “aliphatic” and “cycloaliphatic”, “mono- or polysubstituted” means the mono- or polysubstitution of one or more hydrogen atoms by substituents selected independently of one another from the group consisting of —F, —Cl, —Br, —I, —CN, —NO2, —CHO, ═O, —R0, —C(═O)R0, —C(═O)H, —C(═O)OH, —C(═O)OR0, —C(═O)NH2, —C(═O)NHR0, —C(═O)N(R0)2, —OH, —OR0, —OC(═O)H, —OC(═O)R0, —OC(═O)OR0, —OC(═O)NHR0, —OC(═O)N(R0)2, —SH, —SR0, —SO3H, —S(═O)1-2—R0, —S(═O)1-2NH2, —NH2, —NHR0, —N(R0)2, —N+(R0)3, —N+(R0)2O−, —NHC(═O)R0, —NHC(═O)OR0, —NHC(═O)NH2, —NHC(═O)—NHR0, —NH—C(═O)N(R0)2, —Si(R0)3 and —PO(OR0)2; “aryl”, respectively independently, stands for a carbocyclic ring system with at least one aromatic ring, but without heteroatoms in this ring, wherein, optionally, the aryl residues can be condensed with further saturated, (partially) unsaturated or aromatic ring systems, and each aryl residue can be present in unsubstituted or mono- or polysubstituted form, wherein the aryl substituents can be the same or different and in any desired and possible position of the aryl; “heteroaryl” stands for a 5-, 6- or 7-membered cyclic aromatic residue, which contains 1, 2, 3, 4 or 5 heteroatoms, wherein the heteroatoms, the same or different, are nitrogen, oxygen or sulphur, and the heterocycle can be unsubstituted or mono- or polysubstituted; wherein in the case of the substitution on the heterocycle the substituents can be the same or different and can be in any desired and possible position of the heteroaryl; and wherein the heterocycle can also be part of a bi- or polycyclic system; wherein with respect to “aryl” and “heteroaryl”, “mono- or polysubstituted” means the mono- or polysubstitution of one or more hydrogen atoms of the ring system by substituents selected from the group consisting of —F, —Cl, —Br, —I, —CN, —NO2, —CHO, ═O, —R0, —C(═O)R0, —C(═O)H, —C(═O)OH, —C(═O)OR0, —C(═O)NH2, —C(═O)NHR0, —C(═O)—N(R0)2, —OH, —O(CH2)1-2O—, —OR0, —OC(═O)H, —OC(═O)R0, —OC(═O)OR0, —OC(═O)NHR0, —OC(═O)N(R0)2, —SH, —SR0, —SO3H, —S(═O)1-2—R0, —S(═O)1-2NH2, —NH2, —NHR0, —N(R0)2, —N+(R0)3, —N+(R0)2O−, —NHC(═O)R0, —NHC(═O)OR0, —NH—C(═O)NH2, —NHC(═O)NHR0, —NHC(═O)N(R0)2, —Si(R0)3 or —PO(R0)2; wherein any N-ring atoms present can be respectively oxidised; said compound being in the form of a single stereoisomer or mixture thereof, the free compound and/or a physiologically compatible salt thereof; except for 4-(dimethylamino)-1-methyl-4-p-tolyl cyclohexyl acetate.
地址 Aachen DE